Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04990037
Other study ID # CAN04CLIN003
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 19, 2021
Est. completion date June 15, 2023

Study information

Verified date June 2023
Source Cantargia AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date June 15, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The subject is capable to understand and willing to provide written informed consent before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the subject's disease). - The subject is at least 18 years of age. - The subject has been diagnosed with stage IV PDAC (Pancreatic Ductal Adenocarcinoma) and is amenable to first-line systemic therapy. The subject must have measurable disease that is histologically or cytologically confirmed. - The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1. - The subject has a primary or metastatic lesion amenable to biopsy and is willing to undergo repeat biopsies, unless a biopsy would not be safe in the opinion of the investigator and in agreement by the sponsor and medical monitor (or designee). - The subject has clinically adequate bone marrow, hepatic, and renal function based on clinical laboratory test values at screening within the following ranges: - Creatinine clearance >30 mL/min calculated by Cockcroft-Gault formula - Haemoglobin >90 g/L (blood transfusions during the screening period are not allowed) - Absolute neutrophil count >1.5 × 109/L (usage of growth factors, such as G-CSF (Granulocyte Colony-Stimulating Factor), during the screening period is not allowed) - Platelets >100 × 109/L - Total bilirubin <1.5 × ULN unless due to Gilbert's syndrome - AST and ALT =3 × ULN (or <5 × ULN for subjects with hepatic metastases) - The subject has a QT interval corrected using Fridericia's formula (QTcF) of = 480 milliseconds at screening. - Female subjects of childbearing potential (more info can be found in the protocol) and male subjects with female partners of childbearing potential must be willing to adhere to contraceptive requirements as detailed in the protocol, from at least 1 month prior to study entry to at least 4 months after the last dose of study treatment. - The subject has suitable venous access for safe drug administration and the study- required drug concentration and pharmacodynamic sampling. Exclusion Criteria: - Subjects who have received previous radical radiotherapy, chemotherapy, or investigational therapy for the treatment of metastatic disease. - Prior treatment with 5-FU or gemcitabine administered as a radiation sensitiser during and up to 4 weeks after radiation therapy, is allowed; however, if there is lingering toxicity (Grade >1), then the sponsor should be consulted. - If a subject received adjuvant or neoadjuvant chemotherapy, tumour recurrence or disease progression must have occurred no sooner than 6 months after completing the last dose. - Subjects with uncontrolled brain metastases; however, subjects are allowed if they have been previously treated with surgery, whole-brain radiation, and/or stereotactic radiosurgery and are considered controlled (with =10 mg/day of prednisone or equivalent) at the time of receiving the first dose of CAN04. For asymptomatic subjects, screening brain imaging is not required. - Subjects with endocrine or acinar pancreatic carcinoma. - Subjects with an active severe infection requiring parenteral antibiotics at the time of enrolment or subjects currently receiving oral antibiotics as a continuation of a previous course of parenteral antibiotics. - Subjects with peripheral sensory neuropathy Grade =2. - Subjects with a serious uncontrolled medical disorder that, in the opinion of the investigator or medical monitor, makes it unwise for the subject to participate in the study or that might jeopardise compliance with the protocol. - Subjects with psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs (Adverse Events) or has compromised ability to provide written informed consent. - Subjects with an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting. - Subjects with uncontrolled or significant cardiovascular disease defined as NYHA (New York Heart Association) classification III or IV. - Subjects with congenital long QT syndrome. - Subjects with a history of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses >10 mg/day). - Subjects with known hepatitis B virus surface antigen seropositive or detectable hepatitis C infection viral load. NOTE: Subjects who have positive hepatitis B core antibody or hepatitis B surface antigen antibody can be included but must have an undetectable hepatitis B viral load. - Subjects with a known history of any other relevant congenital or acquired immunodeficiency other than HIV infection. NOTE: Subjects testing positive for HIV are NOT excluded from this study, but HIV- positive subjects must meet the following criteria: - Have CD4+ T-cell (CD4+) counts =350 cells/µL. - Have not had an opportunistic infection within the past 12 months. Subjects on prophylactic antimicrobials can be included in the study. - Should be on established antiretroviral therapy for at least 4 weeks. - Have an HIV viral load less than 400 copies/mL prior to enrolment. - Subjects who receive a live vaccination, etanercept, or other TNF-a (Tumor Necrosis Factor-alpha) inhibitors during or just prior to (within 28 days of first dose of study treatment) participation in this study. - Subjects who have had a hospitalization for bowel obstruction within 12 weeks prior to enrolment. - Subjects with a known bleeding disorder or coagulopathy. NOTE: Subjects on stable anticoagulant therapy are allowed at the discretion of the investigator; however, these subjects should be monitored more frequently. - Subjects with a known or suspected allergy to any study treatment or related products, including platinum-based chemotherapeutic agents. - Female subjects who are pregnant or breastfeeding or trying to become pregnant.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CAN04
Administered intravenously
FOLFIRINOX
Administered intravenously

Locations

Country Name City State
France EDOG - Institut Bergonie - PPDS Bordeaux
France EDOG Institut de Cancerologie de l'Ouest - PPDS Nantes
France EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS Rennes
France Institut de Cancerologie de l'Ouest Saint-Herblain
Spain ICO l'Hospitalet - Hospital Duran i Reynals Barcelona
Spain Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON Barcelona
Spain Hospital General Universitario Gregorio Maranon Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain START MADRID_Hospital Universitario Fundacion Jimenez Diaz Madrid

Sponsors (1)

Lead Sponsor Collaborator
Cantargia AB

Countries where clinical trial is conducted

France,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of TEAEs (Treatment-emergent adverse events) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Number of participants with DTLs (dose-limiting toxicities) Up to day 28
Primary Number of subjects with 1 or more TEAEs leading to dose modifications From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Number of subjects with grade = 3 TEAEs From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Percentage of subjects with grade = 3 TEAEs From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Number of subjects with 1 or more TEAEs leading to treatment discontinuation From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Percentage of subjects with 1 or more TEAEs leading to dose modification From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Number of subjects with 1 or more SAEs (serious adverse events) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Primary Percentage of subjects with 1 or more SAEs From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Serum Concentrations of CAN04 and Folfirnox From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Antidrug antibodies (ADAs) against CAN04 From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Change in serum IL-6 (Interleukin-6) concentration From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Change in serum CRP (C-reactive protein) concentration From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Overall response rate (ORR) Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI Scan) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Progression free survival From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Secondary Overall Survival Up to 36 months after 1st dose of last subject (or death)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04935359 - Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Phase 3
Active, not recruiting NCT05095064 - Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
Active, not recruiting NCT05039177 - A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies Phase 1/Phase 2
Recruiting NCT04888312 - Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients Phase 1/Phase 2
Terminated NCT04390763 - Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Phase 2
Not yet recruiting NCT06206876 - FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Phase 1
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Completed NCT02501902 - Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Phase 1
Active, not recruiting NCT04581343 - A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients Phase 1
Completed NCT02558894 - Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Phase 2
Terminated NCT02732938 - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Phase 2
Recruiting NCT05472259 - A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) Phase 2
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Recruiting NCT02600949 - Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Phase 1
Recruiting NCT05630183 - A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Phase 2
Completed NCT02583477 - Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Phase 1/Phase 2
Terminated NCT04329949 - Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Terminated NCT02101021 - Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Suspended NCT05685602 - CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Phase 1
Not yet recruiting NCT06398587 - Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Phase 2